Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:36:25.646Z.
Calculation as of: 2026-10-06T15:36:25.646Z.
Quote observation: 2026-10-06T15:35:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7afec7845e5c1de7d6a7da79415c7f2016586588c7dc262303e5dc1b6d25f1da
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$4.40M
PS Ratio
N/A
TTM Avg
3681.04
3Y Avg
3681.04
5Y Avg
3681.04
Market Cap
$4.69M
PS Ratio
2.52
TTM Avg
15.60
3Y Avg
53.90
5Y Avg
53.90
Market Cap
$4.33M
PS Ratio
13.62
TTM Avg
8.42
3Y Avg
22.33
5Y Avg
51.13
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | $4.55M | N/A | N/A | N/A | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.40M | N/A | 3681.04 | 3681.04 | 3681.04 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.69M | 2.52 | 15.60 | 53.90 | 53.90 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.33M | 13.62 | 8.42 | 22.33 | 51.13 |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.79M | 24.70 | 40.33 | 58.43 | 54.62 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.20M | 2.06 | 2.70 | 2.70 | 2.70 |
| CalciMedica, Inc. (CALC)vs › | $4.94M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.13M | N/A | 66865.41 | 66865.41 | 66865.41 |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.12M | N/A | 3.25 | 5.35 | 5.73 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
